在接受降尿酸治疗的患者中识别血清尿酸水平与痛风发作的关联:考虑脱落因素的CARES试验事后队列分析
本研究为CARES试验的事后队列分析,纳入6183例接受非布司他或别嘌醇降尿酸治疗的痛风患者,按随访期血清尿酸水平分组评估痛风发作率。结果显示降尿酸治疗第一年内各组发作率相近,36-72个月时血清尿酸与发作率呈剂量反应关系,血清尿酸≥6 mg/dL者发作率持续较高。
要点
- 所有血清尿酸分组痛风发作率峰值出现在0-6个月,与降尿酸治疗启动时间重合。
- 降尿酸治疗第一年内各组痛风发作率相似,36-72个月时呈剂量反应关系(趋势P<0.01)。
- 血清尿酸≥6 mg/dL者在降尿酸治疗第一年后痛风发作率持续较高。
核心结论
- 在考虑删失因素后,降尿酸治疗第一年后血清尿酸≥6 mg/dL时痛风发作率持续较高。
- 停用预防治疗后所有血清尿酸分组发作率均出现峰值,提示可能需要更长的预防治疗持续时间。
研究设计与样本
- CARES试验(痛风患者非布司他与别嘌醇心血管安全性研究)的事后队列分析,参与者随机接受非布司他或别嘌醇,滴定至目标血清尿酸<6 mg/dL,并接受6个月痛风发作预防治疗。
- 共纳入6183例参与者,中位年龄65岁,84%为男性。
主要发现
- 所有血清尿酸分组的痛风发作率峰值均出现在0-6个月,与降尿酸治疗启动时间重合,并在停用预防治疗后6-12个月再次出现峰值。
- 降尿酸治疗初始一年内,各血清尿酸分组间痛风发作率相似。
- 在36-72个月期间,血清尿酸分组与痛风发作率之间呈剂量反应关系,与血清尿酸4.0-5.9 mg/dL相比,血清尿酸≤3.9 mg/dL时发作率较低,血清尿酸≥10 mg/dL时发作率较高(趋势P<0.01)。
关键数值与推荐
- 血清尿酸在每个3-6个月随访时分为≤3.9、4.0-5.9、6.0-7.9、8.0-9.9或≥10 mg/dL五类。
- 主要结局为痛风发作,采用泊松回归模型估计时变血清尿酸分组的痛风发作发生率比,并校正协变量及与参与者保留或脱落相关的因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate gout flare rates based on repeated serum urate (SU) measurements in a randomised controlled trial of urate-lowering therapy (ULT), accounting for dropout and death. METHODS: We performed a secondary analysis using data from Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout, which randomised participants to febuxostat or allopurinol, titrated to target SU <6 mg/dL with flare prophylaxis for 6 months. SU was categorised as ≤3.9, 4.0-5.9, 6.0-7.9, 8.0-9.9 or ≥ 10 mg/dL at each 3-6 month follow-up. The primary outcome was gout flare. Poisson regression models, adjusted for covariates and factors related to participant retention versus dropout, estimated gout flare incidence rate ratios by time-varying SU category. RESULTS: Among 6183 participants, the median age was 65 years and 84% were male. Peak gout flare rates for all SU categories were observed in months 0-6, coinciding with the initiation of ULT and months 6-12 after stopping prophylaxis. Flare rates were similar across SU groups in the initial year of ULT. During months 36-72, a dose-response relationship was observed between the SU category and flare rate. Lower flare rates were observed when SU ≤3.9 mg/dL and greater rates when SU ≥10 mg/dL, compared with SU 4.0-5.9 mg/dL (p for trend <0.01). CONCLUSION: Gout flare rates were persistently higher when SU ≥6 mg/dL after the first year of ULT after accounting for censoring. The spike in flares in all categories after stopping prophylaxis suggests a longer duration of prophylaxis may be warranted.
引用
- Tedeschi SK, Hayashi K, Zhang Y, et al. Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout. Ann Rheum Dis. 2024. PMID: 38724073. doi:10.1136/ard-2024-225761
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。